
Importance: Falls are often viewed as a problem of older age, yet dizziness and balance-related symptoms are common in adulthood and may help identify adults with elevated fall burden. Objective: To examine associations of dizziness and balance-related symptom burden with 12-month fall outcomes in U.S. adults aged 20 to 69 years and whether objective balance impairment adds information beyond symptoms. Design: Cross-sectional study. Setting: National Health and Nutrition Examination Survey 2021 to 2023. Participants: The primary cohort included 6000 adults aged 20 to 69 years with complete symptom and outcome data. Extension analyses included participants with complete Modified Romberg Test data. Intervention or Exposures: Self-reported dizziness/balance-related symptoms in the past 12 months: vertigo, blurred vision with head movement, unsteadiness, and light-headedness/fainting. Secondary exposures were symptom count and objective balance impairment. Main Outcome Measures: Any fall, recurrent falls (≥3), frequent falls (≥5), and fall-related injury in the past 12 months. Survey-weighted quasi-Poisson regression estimated prevalence ratios (PRs) and 95% confidence intervals (CIs). Results: The weighted prevalence of any dizziness/balance-related symptom was 32.7%. After full adjustment, any symptom was associated with any fall (PR, 1.57; 95% CI, 1.40-1.75), recurrent falls (PR, 3.44; 95% CI, 2.81-4.21), frequent falls (PR, 5.09; 95% CI, 3.64-7.13), and fall-related injury (PR, 2.10; 95% CI, 1.66-2.65). Symptom count showed a dose-response relationship across outcomes. Compared with no symptoms, reporting 3 or more symptoms was associated with PRs of 1.97, 5.24, 8.19, and 3.10, respectively. Objective balance impairment alone showed weaker associations, whereas joint symptom-impairment phenotypes better stratified fall burden. Conclusions: Dizziness and balance-related symptom burden were strongly associated with multiple 12-month fall outcomes in U.S. adults aged 20 to 69 years. Objective balance impairment added limited complementary information beyond symptoms. Relevance: Symptom-based assessment may be a practical first step, with objective balance testing used selectively.
Importance: Suspicious thyroid nodules often prompt avoidable surgeries due to diagnostic uncertainty. Although commercial next-generation sequencing assays improve risk stratification, evidence for locally developed sequencing pipelines remains limited. Objective: To evaluate the diagnostic performance of Burapha University-customized whole-exome sequencing (BUU-WES) using preoperative ultrasound-guided core needle biopsy (CNB) specimens, with postsurgical histopathology as the reference standard. Design: Multicenter prospective diagnostic accuracy study. Setting: Four tertiary-care hospitals in Thailand. Participants: Adults (≥20 years) undergoing thyroid surgery for nodules suspicious on ultrasonography (American College of Radiology Thyroid Imaging Reporting and Data System 4-5) and/or cytology (Bethesda I-V). Intervention: DNA extracted from CNB specimens underwent BUU-WES; variants were interpreted using curated databases and published evidence. Main Outcome and Measures: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy with 95% confidence intervals (CIs). Results: Among 82 participants (82 index nodules), malignancy prevalence was 25.6% (21/82). BUU-WES demonstrated sensitivity of 57.1% (95% CI, 34.0%-78.2%), specificity of 86.9% (95% CI, 75.8%-94.2%), PPV of 60.0% (95% CI, 36.1%-80.9%), and NPV of 85.5% (95% CI, 74.2%-93.1%). In nodules ≥1 cm (n = 71), sensitivity increased to 83.3% (95% CI, 51.6%-97.9%), specificity 89.8% (79.2%-96.2%), with NPV 96.4% (95% CI, 87.5%-99.6%). In indeterminate cytology (Bethesda III/IV), BUU-WES showed moderate diagnostic performance, with sensitivity of 60% and specificity and NPV of 86.4%. The most frequently detected alterations involved BRAF , NRAS , and KRAS . Conclusions: BUU-WES primarily functions as a rule-in test due to its high specificity. Its most clinically relevant application is in indeterminate thyroid nodules (Bethesda III/IV), where it serves as an adjunctive tool for risk stratification. Within this subgroup, diagnostic performance is further optimized in nodules ≥1 cm, where the improved NPV suggests potential rule-out applicability in appropriately selected patients.
Importance: Tezepelumab, a monoclonal antibody targeted against thymic stromal lymphopoietin, was recently approved in Canada for the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Its effectiveness specifically in the Canadian setting has not been evaluated. Objective: To analyze the efficacy and safety of tezepelumab in Canadian patients enrolled in the WAYPOINT trial and contextualize the findings with respect to the Canadian healthcare environment. Design: Post hoc analysis of a multinational, parallel-group, randomized, placebo-controlled, Phase 3 trial. Participants: Forty-nine Canadian adult patients with severe uncontrolled CRSwNP. Setting: Subgroup of Canadian patients enrolled in the WAYPOINT trial. Intervention: Tezepelumab 210 mg (n = 25) or placebo (n = 24) administered subcutaneously every 4 weeks for 52 weeks. Main Outcome Measures: The co-primary endpoints were change from baseline to week 52 in endoscopic total nasal polyp score (NPS) and patient-reported bi-weekly nasal congestion score (NCS). Results: The Canadian cohort had higher numbers of patients with asthma and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease than in the full study population. Objective and subjective signs and symptoms of CRSwNP were significantly improved with tezepelumab compared with placebo in the Canadian cohort, including both co-primary endpoints (least squares mean difference vs placebo [95% confidence interval]: total NPS, −2.53 [−3.33 to −1.73], P < .0001; mean NCS, −1.10 [−1.62 to −0.58], P < .0001) and all secondary efficacy endpoints in the overall population. The magnitude of clinical benefit was similar in the Canadian cohort versus the full study population, with less frequent use of rescue therapy (nasal polyp surgery and/or systemic corticosteroids) compared to placebo. The safety profile of tezepelumab was consistent in the Canadian cohort as in the full study population. There were no serious adverse events (AEs) or discontinuations due to AEs in the Canadian cohort. Conclusions: Tezepelumab is an effective and safe treatment for severe uncontrolled CRSwNP in a patient population that is reflective of the Canadian clinical landscape. Relevance: The multinational WAYPOINT trial findings are relevant to patients with CRSwNP routinely seen in Canadian clinical practice, supporting their applicability in the Canadian healthcare context. Trial Registry: WAYPOINT ClinicalTrials.gov number, NCT04851964.
Importance: Dysphagia is frequently observed in patients with posterior fossa tumor (PFT). Surgery can cause either deterioration of or improvement in preexisting dysphagia. In this context, imaging findings might help in predicting postsurgical dysphagic outcomes. Objective: To identify radiological predictors for worsening or improvement in presurgical dysphagia, and for any new onset of postsurgical dysphagia, by analyzing the presurgical brain magnetic resonance imaging (pMRI). Setting: Tertiary referral hospital. Participants: Patients undergoing neurosurgical treatment for PFT. Intervention: Flexible endoscopic evaluation of swallowing, before and after surgery. Main Outcome Measures: pMRI findings (presence of affection of cranial nerves V, VII, IX, X, and XII, ventrocaudal pontine compression, olivary compression, hydrocephalus) associated with postsurgical dysphagia outcomes. Dysphagia severity was rated according to the Fiberoptic Endoscopic Dysphagia Severity Scale (FEDSS). Results: Forty-three patients (60.5% female, 51.5 ± 15.6 years) with PFT-surgery were included. Presurgical dysphagia rate increased from 72.1% (n = 31), with a median FEDSS of 1 (IQR 2 range 1-5), to 79.1% (n = 34). In 46.5% (n = 20) of the cases deterioration of presurgical dysphagia was observed with a median of 1 (IQR 3, range 1-6), while 8 subjects showed a new onset of dysphagia. In 23.3% (n = 10) of the patients, an improvement in presurgical dysphagia was observed. In 2 cases, dysphagia severity decreased from severe to mild. pMRI did not show a significant association with postsurgical dysphagic outcome. Conclusions: Morphological characteristics of the brain tumor prior to surgery are not associated with dysphagia outcome. Besides the small sample size limiting statistical analysis, one may postulate that pMRI findings alone might not suffice to predict dysphagia outcome in patients after PFT-surgery. Relevance: Our study provides insights into possible characteristics of the tumor in relation to dysphagia outcome. Future studies warrant a larger cohort, analysis of intraoperative factors, and findings from postsurgical MRI, to fully understand dysphagia outcome after PFT-surgery.
Importance: Vestibular schwannomas (VSs) frequently cause hearing dysfunction, yet standard clinical assessments may not fully capture neural processing deficits. Objective: To determine whether unilateral VS impairs neural encoding of speech sounds, as measured by frequency-following responses (FFRs), beyond hearing loss alone. Design: Exploratory observational case-control study with both within-subject and matched between-subject comparisons. Setting: Tertiary referral center (Antwerp University Hospital, Belgium). Participants: Twenty-three adults (mean age 53.7 ± 9.8 years; 13 men) with untreated unilateral VS and sufficient residual hearing for FFR assessment were included. Patients with prior VS treatment, neurological disease, middle ear pathology, or profound hearing loss were excluded. VS ears were matched to a previous sensorineural hearing loss (SNHL) cohort by age, sex, and hearing thresholds. Intervention or Exposures: Magnetic resonance imaging-confirmed unilateral VS. Main Outcome Measures: FFR measures of neural encoding of voice pitch were evaluated, with pitch strength as the primary outcome. Additional exploratory FFR measures and formant encoding ( F 1 ) were analyzed. Auditory brainstem response (ABR) latencies and thresholds were also recorded. Results: Within subjects, VS-affected ears showed reduced pitch strength compared with contralateral ears for both the /a/ and /o/ stimulus sections (both P = .023). In the matched comparison with SNHL controls, pitch strength remained significantly reduced ( P = .049 for /a/, P = .043 for /o/), whereas other FFR measures did not differ significantly. ABR analysis showed prolonged wave V latency and interpeak latency I to V in VS-affected ears. Conclusions: VS is associated with reduced neural encoding of voice pitch, most consistently reflected by reduced FFR pitch strength even after accounting for hearing loss. Relevance: These findings suggest a selective vulnerability of temporal pitch coding in VS and support the clinical potential of the FFR as an adjunct measure when standard audiological tests do not fully capture patient-reported listening difficulties.